MAGED4B-specific CD8+T cells were identified in 4/4 HLA-A2pos patients from the Malaysian cohort and 8/11 HLA-A2pos patients from the UK cohort (Figure 1C and Table 2) at a frequency observed at a similar level to neoepitopes in melanoma (range 0.06-0.12%) (40). Here, MAGED4B is linked to melanoma.